Comparison of Diuretic Effect With Furosemide Alone Versus the Combination

Status Recruiting

Clinical Trial Summary

A common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis. The cause of this diuretic resistance is hypothesized to be secondary to hypoalbuminemia which has led some providers to give human albumin in combination with loop diuretics to increase intravascular volume and facilitate diuresis. However, this practice remains controversial because minimal data exists to support its efficacy. The purpose of this study is to compare the efficacy of diuretics alone versus diuretics in combination with albumin in cirrhotic patients presenting with fluid retention.

Clinical Trial Description

The purpose of this single center, prospective study is to compare the efficacy of two strategies for diuresis in patients with cirrhosis, the use of furosemide (Lasix®) alone versus the combination of furosemide (Lasix ®) and albumin (25%). The investigators will perform a single-center, prospective study with data collected as result of standard of care at Rush University Medical Center (RUMC). Patients who are 18 years of age and older, have diagnosed cirrhosis, and present to RUMC with fluid retention will be identified by the Hepatology and/or Surgery attending and be screened for inclusion in the study. Each patient will be randomized into one of the two cohorts and will have 50% chance of being placed into either cohort. Cohort 1 will receive furosemide (Lasix) 40 to 80 mg intravenous push (IVP) twice a day (BID) for at least 48 hours and cohort 2 will receive combination of furosemide (Lasix) 40 to 80 mg IVP BID and albumin (25%) 12.5 grams BID for at least 48 hours. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04216784
Study type	Interventional
Source	Rush University Medical Center
Contact	Nicole Alvey
Phone	312-942-2024
Email	nicole_alvey@Rush.edu
Status	Recruiting
Phase	Phase 4
Start date	December 19, 2019
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05793983` - S100A8/A9 and Innate Immunity in Liver Disease
Completed	`NCT04604860` - Use of EL-FIT App to Promote Physical Activity	N/A
Recruiting	`NCT05928624` - A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients	N/A
Active, not recruiting	`NCT01438970` - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function	Phase 2
Recruiting	`NCT05998330` - LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease	N/A
Completed	`NCT04581369` - Cirrhosis Medical Home	N/A
Withdrawn	`NCT04244877` - Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility	Phase 3
Recruiting	`NCT04588077` - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis	Phase 4
Recruiting	`NCT05538962` - Longitudinal Monitoring of Inflammation in Cirrhosis	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Completed	`NCT03850977` - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Active, not recruiting	`NCT03736265` - Carvedilol for Prevention of Esophageal Varices Progression	N/A
Recruiting	`NCT04530760` - Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
Recruiting	`NCT05093218` - Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.	N/A
Recruiting	`NCT03437876` - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis	N/A
Recruiting	`NCT05604274` - Longitudinal Monitoring of Stool Characteristics
Recruiting	`NCT04867954` - Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
Completed	`NCT04643795` - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects	Phase 1
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed	`NCT04121520` - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms